The chief executive of Deutsche Boerse on Thursday said its planned merger with London Stock Exchange was still a long way off, even if European regulators should give it the green light.
“There are a series of national and regional approvals still pending after that,” Deutsche Boerse CEO Carsten Kengeter said at an economic conference in reference to an investigation by European antitrust regulators.
“So it is still not clear at all that everything will work out,” Kengeter added.
Concerned the $28 billion tie-up could hinder competition in key financial market activities, the EU has opened a full investigation into the deal and the European Commission is expected to detail its objections in the second week of December.
Both companies can appeal against these or make concessions.
A thumbs up from the EU would then require the local watchdog in Germany’s state of Hesse, where Deutsche Boerse is based, to approve the merger. Sources had previously told Reuters the regulator was concerned over a loss of power if Deutsche Boerse became part of the larger London-based group.
The owner of the Frankfurt stock exchange is obliged by law to support the development of Frankfurt as a centre for securities trading and Hesse’s market watchdog has yet to give its view on the planned merger.
Full Content: Reuters
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Intel Challenges €376 Million EU Antitrust Fine in Ongoing Legal Battle
May 18, 2025 by
CPI
FTC Chairman Highlights Fiscal Responsibility and Consumer Protection in House Testimony
May 18, 2025 by
CPI
Microsoft Moves Closer to Settling EU Antitrust Case Over Teams Integration
May 18, 2025 by
CPI
Meta Moves to Dismiss FTC Antitrust Case Amid Ongoing Trial
May 18, 2025 by
CPI
Meta Begins Defense After FTC Concludes Case in Landmark Antitrust Trial
May 15, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas